Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico

Launched by INSTITUTO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION SALVADOR ZUBIRAN · Mar 22, 2022

Keywords

ClinConnect Summary

This is an observational study to estimate the prevalence of germline mutations in patients with pancreatic cancer. Eighty four genes will be analyzed, all of which have been associated with hereditary cancer. The genes are included on Invitae Multi-Cancer Panel ®, performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology. The 84 genes include: AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA1, DICER1, DIS3L2, EGFR, EPCAM, FH, FLCN, GATA2, GPC3, G...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Female and male participants ≥ 18 years of age.
• • Diagnosed within the previous 6 months with histologically confirmed pancreatic adenocarcinoma stage I to IV.
• • Participant provides written informed consent for the study.
• • Participant must agree to sample collection and genetic testing using the Invitae Multi-Cancer Panel ®.
• Exclusion Criteria:
• • Diagnosed with pancreatic adenocarcinoma more than 6 months before presenting to the clinical site.
• • Diagnosed with intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, pancreatic neuroendocrine tumors.